SUPRIYA Supriya Lifescience Q3 FY26 results (Oct–Dec 2025) and concall
Supriya Lifescience reported a solid Q3 FY26 with 11% YoY revenue growth to ₹206 crores and a strong 35% EBITDA margin. Exports remained a significant contributor, and new product launches are progressing. The Ambernath facility is set for capitalization in Q4 FY26, though its EU inspection is delayed. Management remains confident in achieving its FY26 revenue guidance and long-term targets, emphasizing strategic focus on regulated markets and backward integration.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 10.8%, net profit up 6.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 166 | 186 | 184 | 145 | 200 +20% | 206 +11% |
| EBITDA | 65 | 66 | 68 | 52 | 73 +12% | 72 +9% |
| Net profit | 46 | 47 | 50 | 35 | 50 +9% | 50 +6% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
